Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Chinese drugmaker Innogen expects to complete a late-stage clinical trial of its experimental weight-loss drug candidate next ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

The U.S. Food and Drug Administration said on Monday it is revising the labeling of all extended-release stimulants used to ...

Novo Nordisk A/S and Eli Lilly & Co, the pharmaceutical giants dominating the global obesity drug market, now face their ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

For reference, Novo Nordisk also offers a highly successful weight loss drug, Wegovy, a GLP-1 receptor agonist.

Senior Advocate Diya Kapur, representing the petitioner, informed the court that some gyms were promoting these drugs as a ...

Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...

Mounjaro has become popular as a weight loss drug but it also seems to be linked to hair loss in some cases in a worrying new ...

The proceedings follow a PIL seeking a ban on sale of weight loss drugs that are still undergoing clinical trials ...